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Abstract
Background: Mandatory generic substitution (GS) was introduced in Finland on 1 April 2003. The aim of this study
was to explore and compare the impacts of GS on the activities of pharmaceutical companies representing mainly
original or generic pharmaceutical products in Finland. The self-reported impact of GS from pharmaceutical
companies’ perspective was explored with a focus on the number of employees, the range of sales packages on
the market, the marketing activities, the research and development of new pharmaceutical products and storage of
pharmaceuticals.
Methods: A cross-sectional postal survey was conducted among pharmaceutical companies with an office in
Finland and substitutable medicines in the Finnish pharmaceutical market one year (2004) and five years (2008)
after the introduction of GS. Completed questionnaires were returned by 16 original and 7 generic product
companies in 2004 (response rate 56%, n = 41) and by 16 original and 6 generic product companies in 2008
(response rate 56%, n = 39). Descriptive statistical analyses were performed.
Results: The number of employees (2004: n = 6/16, 2008: n = 7/16) and the amount of prescription medicine
marketing (2004: n = 7/16, 2008: n = 8/16) decreased in many of the original product companies after the
introduction of GS. GS resulted in problems related to the storage of pharmaceuticals in the original product
companies shortly after GS was introduced (p = 0.032 between 2004 and 2008). In the generic product companies,
the prescription medicine representatives’ visits to pharmacies increased at the beginning of GS (p = 0.021
between 2004 and 2008). In addition, GS caused problems with the storage of pharmaceuticals one year and five
years after the reform (2004: n = 4/7, 2008: n = 3/6). The differences between original and generic product
companies regarding the impacts of GS were not, however, statistically significant. GS did not affect on the range
of sales packages on the market or the research activities of the majority of companies.
Conclusions: The study suggests that GS has had impacts on the activities of pharmaceutical companies in
Finland. There were also some differences, although not statistically significant, between the surveyed original and
generic product companies regarding the self-reported impacts of GS. More investigations are needed in this field.
* Correspondence: johanna.timonen@uef.fi
1School of Pharmacy/Social Pharmacy, Faculty of Health Sciences, Kuopio
Campus, University of Eastern Finland, P.O.Box 1627, FI-70211 Kuopio,
Finland
Full list of author information is available at the end of the article
Timonen et al. BMC Clinical Pharmacology 2010, 10:15
http://www.biomedcentral.com/1472-6904/10/15
© 2010 Timonen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Increasing pharmaceutical expenditures have been a
common problem in many western countries. One way
to curb growth in pharmaceutical expenditures is
through generic substitution (GS). GS has been intro-
duced in at least 22 European countries [1-3] and in
most states in the United States [4]. The purpose of GS is
to increase dispensing of less expensive generic medi-
cines and to decrease the price of pharmaceutical pro-
ducts through price competition. GS has successfully
promoted the sales of less expensive medicines [5-7] and
decreased the prices of pharmaceutical products [8-11] in
several countries, and thus has effectively reduced growth
in the pharmaceutical expenses of society and patients,
for example in Sweden [12] and Finland [13].
GS has been a considerable pharmaceutical policy
reform in many countries, not merely for society and
patients, but also for parties involved in the pharmaceuti-
cal distribution chain (pharmaceutical companies, whole-
sale pharmaceutical companies and pharmacies). Even
though GS has been introduced in many countries, there
is a limited number of research publications in this area.
Several studies have investigated pharmacists’ opinions
regarding GS and the implementation of GS in pharmacies
in different countries [14-18]. Some studies have reported
pharmacy owners’ experiences of the impacts of GS on
pharmacies in Denmark [15] and Finland [19]. The impact
of GS on the activities of wholesale pharmaceutical com-
panies [20], as well as the impact of GS on the sales of
pharmaceutical companies [7] have been explored in
Finland. However, there are no published studies concen-
trating on the impacts of GS on the activities, other than
competition [8,10,11], of pharmaceutical companies.
Mandatory GS was introduced in Finland on 1 April
2003. Since then pharmacists have been obligated to
substitute the least expensive or close to the least
expensive medicine for a prescribed medicine if the pre-
scribed medicine is not within the price corridor and
the physician or the customer do not object to the sub-
stitution [21]. The price corridor is determined quarterly
by the least expensive medicine in every substitution
group, and it includes all the substitutable medicines
with a price difference of less than €2 in products priced
under €40, and of less than €3 in products priced €40 or
more. Substitutable medicines are included on a list of
interchangeable medicines compiled by the Finnish
Medicines Agency [22]. Interchangeable medicines con-
tain the same active ingredient in the same quantity,
have the same pharmaceutical form (exception: tablets
are substitutable for capsules and capsules for tablets),
are bioequivalent and belong to a pharmaceutical group
in which substitution can be performed safely. At the
beginning of 2009, the list of interchangeable medicines
comprised about 42% (n = 2 797) of the human phar-
maceutical products with a marketing authorization in
Finland (n = 6 694) [23].
Between 2003 and 2008, GS was possible for 12-24 mil-
lion prescriptions reimbursed annually [21]. Customers
objected to GS for 10-12% of dispensings and physicians
objected for 0.2-0.4% of dispensings. The annual direct
savings of the substitutions for patients and for society
have been €26-36 million. GS also stimulated significant
price competition between pharmaceutical companies
[11], and estimated savings from the reduced price of
medicines have been €34-59 million annually [13,21].
The pharmaceutical industry objected to GS before it
was introduced [24,25]. According to the research-based
pharmaceutical industry, promoting the use of generic
products was desirable, but it should be achieved by allow-
ing normal competitive mechanisms to function, not by
mandatory GS [24]. In addition, it was argued that GS
would have an impact on the pharmaceutical companies
and their everyday activities, such as marketing [26] and
the storage of pharmaceutical products [24]. It was also
argued that GS would raise drug safety issues [24,26],
decrease the range of different packages (e.g. strength,
size, pharmaceutical form) of pharmaceutical products for
sale, and reduce incentives for research and development
of new pharmaceutical products in Finland [27].
The aim of this study was to explore and compare the
impact of GS on the activities of pharmaceutical compa-
nies representing mainly original or generic pharmaceu-
tical products from the companies’ perspective one year
and five years after the introduction of GS in Finland.
The self-reported impact of GS was explored with a
focus on the number of employees, marketing activities,
the range of sales packages on the market, research and
development (R&D) of new pharmaceutical products
and storage of pharmaceuticals. Results reported in this
article are part of a larger study exploring the impact of
GS for pharmaceutical companies in Finland. Results
concerning impact of GS on the turnover and gross
margin of pharmaceutical companies have been pub-
lished elsewhere [7].
Methods
Two cross-sectional postal surveys were conducted one
year (June-August 2004) and five years (November
2007-January 2008) after the introduction of GS. Ques-
tionnaires were sent to all pharmaceutical companies
with an office in Finland and that market one or more
substitutable medicines in Finland. The questionnaire
was addressed to the key person in the company, such
as the managing director or the sales and marketing
director. The list of companies was obtained from the
National Agency for Medicines’ ( N A M )l i s to ft h e
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Pharma Industry Finland’s (PIF) list of member compa-
nies. The NAM list included pharmaceutical companies
that have Finland as their home country in the NAM’s
r e g i s t e ra n dt h a th o l do n eo rm o r ev a l i dm a r k e t i n g
authorizations in Finland. PIF is a trade association for
research-based pharmaceutical companies in Finland
and most research-based pharmaceutical companies
operating in Finland are members of PIF.
The Finnish pharmaceutical reference book (Pharmaca
Fennica) on the Internet, and the current list of inter-
changeable medicines produced by NAM, were used to
verify which companies marketed substitutable medi-
cines in Finland. In 2008, the Medicinal product search
service at the NAM’sw e bs i t ew a sa l s ou s e d ,b u ti td i d
not exist in 2004.
The lists of the NAM and PIF included 95 pharmaceu-
tical companies or other parties operating in the Finnish
pharmaceutical market in 2004. Of these, 43 pharmaceu-
tical companies fulfilled the inclusion criteria (marketed
substitutable medicines in the Finnish pharmaceutical
market and had an office in Finland). The questionnaire
was posted to all these 43 companies. After one remin-
der, 25 (58%) questionnaires were returned. However,
two of the returned questionnaires were not included in
the study because the company reported that they did
not presently have substitutable medicines in the Finnish
pharmaceutical market. Consequently, a total of 41 phar-
maceutical companies (25 represented original products,
9 represented generic products and 7 represented both
products) fulfilled the inclusion criteria, from which 23
(56%) companies returned completed and usable
questionnaire.
In 2007-2008, the lists of the NAM and PIF contained
93 pharmaceutical companies or other parties operating
in Finland. The questionnaire was sent to all 39 pharma-
ceutical companies (19 represented original products, 10
represented generic products, 7 represented both pro-
ducts and 3 represented parallel imported products) that
marketed substitutable medicines in the Finnish pharma-
ceutical market and had an office in Finland. Of these
companies, 29 were the same as in 2004. Three remin-
ders were needed in the 2008 survey to achieve the same
response rate than in 2004. After three reminders, 23
(59%) companies returned the questionnaire. However,
one of the returned questionnaires was not complete and
it was not included. Consequently, a total of 22 (56%)
questionnaires were included in the final data analyses.
In 2004, the survey questionnaire included 37 struc-
tured or open-ended questions and one Likert-scale
question. Responses to seven structured questions and
two open-ended questions are reported in this article. In
2007-2008, the questionnaire included 27 questions, both
structured and open-ended. The questions reported in
this article were the same in 2004 and in 2007-2008, with
the exception the minor changes described below. The
questions related to the impact of GS on the number of
employees, the amount of prescription medicine market-
ing, the prescription medicine representatives’ visits to
pharmacies and to physicians, the number of different
packages of pharmaceutical products for sale, R&D of
new pharmaceutical products and storage of pharmaceu-
ticals. The questions were selected on the basis of debate
about the possible impact of GS before it was introduced.
The self-reported impact of GS on the number of
employees, marketing activities, the range of packages for
sale and R&D was elicited using similar structured ques-
tions. For example, the impacts of GS on the number of
employees in the company were investigated with ques-
tion, “Has generic substitution influenced the number of
employees in your company?”. The question had four
response options: 1. No, 2. The number of employees has
decreased, 3. The number of employees has increased, 4.
Some other impact. In the fourth response option, the
respondents were also requested to report what kind of
impact. If the respondent answered that the number of
employees had increased or decreased, they were asked
to specify by how many employees. Respectively, if the
respondent answered that the number of packages for
sale had increased or decreased, they were asked to spe-
cify by the decrease or increase per cent in the number of
packages. In 2004, an open-ended question was used to
determine which department within each company was
most impact on the number of employees by GS. In the
2007-2008 survey this information was sought using a
structured question formulated using the results of the
2004 survey. The impact of GS on the storage of pharma-
ceuticals was investigated using a structured question
with a list of seven options in 2004 and eight options in
2008, with respondents given the possibility to select sev-
eral options. In all questions in 2004 and 2007-2008 sur-
veys, the impact was assessed since the introduction of
GS in Finland.
The data were analyzed with SPSS 14.0 statistical soft-
ware. A descriptive approach was used in the analyses,
using frequencies and cross-tabulations and Fisher’s
Exact test for a group comparison within the survey and
between the surveys. Differences in the background
characteristics between study companies in the 2004
and 2008 surveys were tested with Fisher’s Exact tests
and Mann-Whitney U tests. The significance level was
defined as p-values ≤0.05.
Results
Background characteristics
Of the pharmaceutical companies that responded to the
survey in 2004, 12 represented original products, 4
represented generic products and 7 represented both
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represented both products, 4 companies reported that
they represent mainly original products and 3 compa-
nies reported that they represent mainly generic pro-
ducts. Of the companies that responded to the survey in
2008, 13 represented original products, 3 represented
generic products and 6 represented both. Of the compa-
nies that represented both, 3 companies reported that
they represent mainly original products and 3 compa-
nies reported that they represent mainly generic pro-
ducts. Because the number of study companies was
small, the companies were categorized as companies
that represented mainly original pharmaceutical pro-
ducts (original product companies) and companies that
represented mainly generic pharmaceutical products
(generic product companies). The background charac-
teristics of the study companies in the 2004 and 2008
surveys are shown in Table 1. There were no statistically
significant differences between the 2004 and 2008 survey
groups of original product companies and generic pro-
duct companies.
Impact of GS on the number of employees
GS was reported to affect on the number of employees in
most (2004: n = 9/16, 2008: n = 9/16) of the original pro-
duct companies in both surveys and in most (n = 5/7) of
the generic product companies in the 2004 survey
(Table 2). In the original product companies the number
of employees decreased (2004: n = 6, 2008: n = 7), and in
the generic product companies the number of employees
increased (2004: n = 3). In the 2008 survey, most (n = 4/
6) of the generic product companies reported that GS
had not impacted the number of employees, but the dif-
ference with the 2004 survey was not statistically signifi-
cant (p = 0.283). In addition, the differences between the
original and generic product companies were not statisti-
cally significant in the 2004 (p = 0.063) and 2008 (p =
0.814) surveys. Table 3 indicates that GS mainly affected
the number of employees in the sales and marketing
departments in the study companies.
Of the original product companies with a decreased
number of employees (2004: n = 6, 2008: n = 7), five in
2004 and four in 2008 reported a decrease in the number
of employees since the introduction of GS. These compa-
nies reported a total decrease of 81 people (median 5,
range 2-60) in the 2004 survey and 33 people (median 5.5,
range 2-20) in the 2008 survey. In the 2008 survey, two of
the original product companies reported an increase in
number of employees, which was a total of five people.
For the generic product companies that reported
increased number of employees in the 2004 survey (n =
3), the total increase was nine people (median 3, range 2-
4) since the introduction of GS. For those companies that
reported a decreased number of employees (n = 2) in the
2004 survey the total decrease was nine people. In the
2008 survey, only one of the generic product companies
with a decreased number of employees gave the number
of decreased employees, which was two employees.
Impact of GS on the marketing of pharmaceutical
products
Table 4 summarizes the impact of GS on the marketing
activities of the study companies. In both surveys, more
than half (2004: n = 9/16, 2008: n = 9/16) of the original
product companies reported that GS had impacted the
amount of prescription medicine marketing. Of these,
most companies (2004: n = 7, 2008: n = 8) had decreased
the amount of marketing after GS. In the generic product
companies GS was reported to affect the prescription
medicine representatives’ visits to the pharmacies (n = 5/
7) in the 2004 survey, but in the 2008 survey, most (n =
5/6) of the generic product companies reported that GS
had not affected the representatives’ visits to pharmacies
(p = 0.021). The differences between original and generic
product companies in relation to their marketing activ-
ities were not statistically significant in the 2004 and
2008 surveys (Table 4).
Impact of GS on the range of sales packages of
pharmaceutical products on the market
Most of the original product companies in both surveys
(2004: n = 8/15, 2008: n = 8/14) and most of the generic
product companies in the 2004 survey (n = 4/7)
reported that GS had not impacted the number of dif-
ferent sales packages on the market (Table 5). In the
2008 survey, two-thirds (n = 4/6) of the generic product
companies reported that GS had influenced the number
of different packages for sale, but the differences
between the companies (p = 0.347) or surveys (p =
0.790) were not statistically significant.
Among the original product companies that reported
a decrease in the number of sales packages on the mar-
ket (2004: n = 7/15, 2008: n = 5/14) the median
decrease in the number of packages was 10% (range 0.5-
20%) in the 2004 survey. In the 2008 survey, three of
the original product companies reported an average
decrease of 15% (range 5-20%) of packages sold. Among
the two generic product companies that reported a
decrease in the number of packages for sale in the 2004
survey, the number of packages had decreased 3% and
10%. In the 2008 survey the generic product companies
that reported a decreased number of sales packages (n =
2) did not report the percentage decrease.
Impact of GS on the R&D of new pharmaceutical products
in Finland
In both surveys, the majority of original (2004: n = 8/14,
2008: n = 8/12) and generic (2004: n = 2/3, 2008: n = 3/4)
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Survey 2004
n of respondents (%)
Survey 2008
n of respondents (%)
P-value
Number of companies 1.000
All 23 22
Original products 16 (70) 16 (73)
Generic products 7 (30) 6 (27)
Number of employees
Original product companies 0.732
≤19 1 (7) 4 (25)
20-49 1 (7) 2 (13)
50-99 7 (50) 5 (31)
100-149 2 (14) 2 (13)
≥150 3 (22) 3 (19)
Generic product companies 0.470
≤19 5 (71) 2 (40)
20-49 - -
50-99 2 (29) 1 (20)
100-149 - 1 (20)
≥150 - 1 (20)
Turnover of the companies (€)
a
Original product companies 0.381
≤1,000,000 - -
1,000,001-20,000,000 1 (7) 6 (37)
20,000,001-40,000,000 5 (36) 2 (13)
40,000,001-60,000,000 3 (22) 3 (19)
60,000,001-80,000,000 2 (14) 1 (6)
80,000,001-100,000,000 1 (7) 2 (13)
≥100,000,001 2 (14) 2 (13)
Generic product companies 0.755
≤1,000,000 1 (14) 1 (17)
1,000,001-20,000,000 5 (72) 3 (50)
20,000,001-40,000,000 1 (14) -
40,000,001-60,000,000 - 1 (17)
60,000,001-80,000,000 - -
80,000,001-100,000,000 - -
≥100,000,001 - 1 (17)
Median proportion (%) of turnover coming from the sale of pharmaceutical products included on the list of interchangeable
medicines
b
All 25 (range 1.5-100) 11 (range 1-93) 0.749
Original product companies 23 (range 1.5-80) 8.5 (range 1-70) 0.527
Generic product companies 30 (range 5-100) 45 (range 5.4-93) 0.836
Median proportion (%) of turnover coming from the sale of pharmaceutical products included in the price corridor
b
All 10 (range 0-90) 8.2 (range 0-90) 0.767
Original product companies 7.5 (range 0-50) 3.5 (range 0-70) 0.608
Generic product companies 30 (range 5-90) 45 (range 5.4-90) 0.836
Median market share (%) in the Finnish pharmaceutical market
b
All 1.9 (range 0.1-10) 1.9 (range 0.1-9) 0.904
Original product companies 3.8 (range 0.6-10) 2.0 (range 0.3-8) 0.354
Generic product companies 0.3 (range 0.1-2) 0.3 (range 0.1-9) 0.662
aThe companies reported their turnover from 2003 in the 2004 survey and from 2006 in the 2008 survey.
bThe companies reported their proportion (%) from 2006 in the 2008 survey.
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ceutical products reported that GS had not influenced
their R&D in Finland (Table 6).
Impact of GS on the storage of pharmaceutical products
GS was reported to affect the storage of pharmaceutical
products in most of the original (n = 12/16) and generic
(n = 4/7) product companies in the 2004 survey
(Table 7). In the 2008 survey, most (n = 10/15) of the
original product companies reported that GS had not
impacted the storage of pharmaceutical products, and
the difference compared to the responses of the original
product companies in the 2004 survey was statistically
significant (p = 0.032). Of the generic product compa-
nies, half (n = 3/6) reported that GS had impacted the
storage in the 2008 survey. In the original product
companies GS had most often caused over-stocking
(2004: n = 9/16) and problems with the expiry dates
(2004: n = 7/16). Problems with expiry dates (2004: n =
4/7, 2008: n = 3/6) and the availability (2008: n = 3/6)
of pharmaceutical products were the most commonly
reported problems by the generic product companies.
The differences between original and generic product
companies were not, however, statistically significant.
Discussion
In this study the impacts of GS on the activities of phar-
maceutical companies representing mainly original or
generic pharmaceutical products were investigated one
year and five years after the introduction of GS in
Finland. The original product companies self-reported
that GS had impacted the number of employees and the
Table 2 Impact of generic substitution on the number of employees in the pharmaceutical companies
Survey 2004 Survey 2008
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Has generic substitution influenced the
number of employees in your company?*
0.063 0.814
No 7 (44) 2 (29) 9 (39) 7 (44) 4 (67) 11 (50)
Number of employees has decreased 6 (37) 2 (29) 8 (35) 7 (44) 2 (33) 9 (41)
Number of employees has increased - 3 (43) 3 (13) 2 (12) - 2 (9)
Some other impact
a 3 (19) - 3 (13) - - -
Total 16 (100) 7 (100) 23 (100) 16 (100) 6 (100) 22 (100)
* P-value between the 2004 and 2008 surveys in the original product companies (p = 0.210) and in the generic product companies (p = 0.283)
a Employees have been reassigned to another post, openings in the company have not been filled.
Table 3 Companies’ departments most impacted on the number of employees by the introduction of generic
substitution
Survey 2004 Survey 2008
Pharmaceutical companies
(n = 11)
a
n (%)
b
Pharmaceutical companies
(n = 11)
n(%)
b
Number of employees has decreased
Sales and marketing 6 (54) 8 (73)
Marketing authorization and reimbursement - 1 (9)
Research and development - 1 (9)
Logistics - -
Management - 1 (9)
Number of employees has increased
Sales and marketing 3 (27) 1 (9)
Marketing authorization and reimbursement - 1 (9)
Research and development - -
Logistics 1 (9) -
Management - -
Some other impact
Sales and marketing 2 (18) -
a Two original product companies and one generic product company did not report the department, in which GS had influenced on the number of employees.
b The companies could report several departments.
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five years after the introduction of GS. In addition, GS
caused problems related to the storage of pharmaceutical
products shortly after it was introduced. According to
the generic product companies, GS affected the prescrip-
tion representatives’ v i s i tt op h a r m a c i e sa tt h eb e g i n n i n g
of the reform. Furthermore, GS caused problems with
the storage of pharmaceutical products one year and five
years after the introduction. However, the differences
between original and generic product companies regard-
ing the impacts of GS were not statistically significant in
this study. This might be because of the small study
population.
After the introduction of GS the number of employees
had decreased in many of the original product companies
and, especially in the sales and marketing departments.
The findings are in line with the statistics of PIF, where
the number of employees increased steadily between
1990 and 2002 [28], but decreased after 2003 almost
without exception [29-33]. In contrast at a European
level the number of employees in the pharmaceutical
industry was stable during the same period [34]. In
Finland, the estimation of the overall decrease in employ-
ees is about 800-900 people between 2003 and 2008, due
to the mergers of companies and downsizing e.g. espe-
cially in the marketing, but also in R&D [29-33]. In 2008,
the total number of employees in the pharmaceutical
industry was about 6 000 people. GS stimulated competi-
tion in the Finnish pharmaceutical market [11,35]. Redu-
cing the number of employees was one response to this
new competition between the companies in Finland [7].
However, the decrease in the number of employees may
also reflect increased competition in the pharmaceutical
market globally.
Many of the original product companies also reported
a decrease in the amount of prescription medicine mar-
keting after GS. Original product companies often
decrease their promotional activities (e.g. the marketing
of product) when the generic competition begins [36].
In an earlier study, reduction in original product
Table 4 Impact of generic substitution on the marketing of pharmaceutical products in the pharmaceutical companies
Survey 2004 Survey 2008
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Has generic substitution influenced the
amount of prescription medicine marketing?*
0.103 1.000
No 7 (44) 4 (57) 11 (48) 7 (44) 3 (50) 10 (45)
Marketing has decreased 7 (44) 1 (14) 8 (35) 8 (50) 3 (50) 11 (50)
Marketing has increased - 2 (29) 2 (9) 1 (6) - 1 (5)
Some other impact
a 2 (12) - 2 (9) - - -
Total 16 (100) 7 (100) 23 (100) 16 (100) 6 (100) 22 (100)
Has generic substitution influenced
prescription medicine representatives’ visits to
pharmacies?**
0.120 0.619
No 9 (60) 2 (29) 11 (50) 10 (62) 5 (83) 15 (68)
Visits have decreased 2 (13) - 2 (9) 2 (13) 1 (17) 3 (14)
Visits have increased 3 (20) 5 (71) 8 (36) 4 (25) - 4 (18)
Some other impact
b 1 (7) - 1 (5) - - -
Total 15 (100) 7 (100) 22 (100) 16 (100) 6 (100) 22 (100)
Has generic substitution influenced
prescription medicine representatives’ visits to
physicians?***
1.000 0.802
No 10 (63) 5 (71) 15 (65) 9 (60) 4 (67) 13 (62)
Visits have decreased 5 (31) 2 (29) 7 (31) 5 (33) 1 (17) 6 (29)
Visits have increased - - - 1 (7) 1 (17) 2 (9)
Some other impact
c 1 (6) - 1 (4) - - -
Total 16 (100) 7 (100) 23 (100) 15 (100) 6 (100) 21 (100)
* P-value between the 2004 and 2008 surveys in the original product companies (p = 0.624) and in the generic product companies (p = 0.372).
** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 0.021).
*** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 1.000).
a Marketing of pharmaceutical products within generic substitution has ended, marketing has been segmented and allocated.
b The content of marketing has been changed.
c Marketing has been focused on pharmaceutical products that do not include generic substitution and on new products.
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reported mechanism compensate for increased competi-
tion due to GS [7].
Generic product companies reported increased market-
ing activities directed to pharmacies in the early stage of
GS. This is in line with a study conducted among Finnish
pharmacists [37]. The finding is logical given that phar-
macists play an important role when a patient decides
whether or not to object to switching [17,38,39]. Market-
ing in the early stages following the introduction of GS
may also provide a competitive advantage [40]. Previous
Finnish studies have reported that GS has also changed
the content of drug marketing directed to pharmacies,
with a greater emphasis on price after GS [37,41].
Both the original and generic product companies
reported difficulties in stock management, especially
among the original product companies in the early stages
of GS. Sales by the volume of generic pharmaceutical
products have increased whereas sales by volume of
original products have decreased after GS [42]. This may
be one reason for some of the storage problems reported,
such as overstocking by the original product companies.
The market situation also changed more often after GS,
because the price corridor is determined quarterly and
prices of pharmaceutical products can be updated every
two weeks. This also creates challenges for stock manage-
ment. Previous studies have reported that stock manage-
ment has also become more complicated in Danish [15]
and Finnish [19] pharmacies as well as in Finnish whole-
sale pharmaceutical companies [20] due to GS.
Our findings did not strongly support the belief that
GS would decrease the range of different packages (e.g.
strength, size, pharmaceutical form) of pharmaceutical
products for sale as it was anticipated before GS was
introduced in Finland [27]. Furthermore, the results did
not reveal that GS had impacted R&D in pharmaceutical
companies. However, there were several companies that
reported they decreased the number of packages for sale
Table 5 Impact of generic substitution on the range of sales packages on the market in the pharmaceutical companies
Survey 2004 Survey 2008
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Has generic substitution influenced the number of
different sales packages of pharmaceutical products on
the pharmaceutical market in your company?*
0.318 0.347
No 8 (53) 4 (57) 12 (54) 8 (57) 2 (33) 10 (50)
The number of packages has decreased 7 (47) 2 (29) 9 (41) 5 (36) 2 (33) 7 (35)
The number of packages has increased - 1 (14) 1 (5) 1 (7) 2 (33) 3 (15)
Total 15 (100) 7 (100 22 (100) 14 (100) 6 (100) 20 (100)
* P-value between the 2004 and 2008 surveys in the original product companies (p = 0.710) and in the generic product companies (p = 0.790).
Table 6 Impact of generic substitution on research and development of new pharmaceutical products
a
Survey 2004 Survey 2008
Original
product
companies
n (%)
a
Generic
product
companies
n (%)
Total
n (%)
b
P-
value
Original
product
companies
n (%)
Generic
product
companies
n (%)
Total
n (%)
P-
value
Has generic substitution influenced the
research and development of new
pharmaceutical products in Finland in
your company?*
0.161 0.154
No 8 (57) 2 (67) 10 (59) 8 (67) 3 (75) 11 (69)
Research and development has
decreased
5 (36) - 5 (29) 4 (33) - 4 (25)
Research and development has
increased
- 1 (33) 1 (6) - - -
Some other impact
c 2 (14) - 2 (12) - 1 (25) 1 (6)
Total 14 (107) 3 (100) 17 (106) 12 (100) 4 (100) 16 (100)
* P-value between the 2004 and 2008 surveys in the original product companies (p = 0.594) and in the generic product companies (p = 1.000)
a The table contains only the responses of companies that conducted research and development of new pharmaceutical products.
bOne company chose two impacts (research and development has decreased and some other impact).
cFor example, the research of pharmaceutical products within generic substitution does not interest no longer, research and development will be directed to
new pharmacotherapy areas.
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Finland. Accordingly, more detailed research on these
topics are needed.
The study had some limitations. The survey question-
naires were posted to all companies that market substitu-
table medicines and had an office in Finland in 2004 and
in 2007-2008. The response rate in both surveys was 56%.
This is comparable or higher than in some survey studies
posted to pharmaceutical companies [43,44] or companies
from different industries in Finland [43,45], in which
response rate has varied between 24 and 52%. However,
the study population was small and this should be taken
into account when interpreting the results of this study.
This meant that, the categories of generic product compa-
nies and original product companies also included compa-
nies that marketed both original and generic products. If
the study companies had been categorized differently, the
results might have been different in some activities and
between groups. In addition, pharmaceutical companies
that marketed only generic or original products were
slightly underrepresented among the survey respondents.
This means caution is needed when generalizing the
results of this study.
It should also be noted that results of this study are
based on self-reports from the key persons of pharma-
ceutical companies. Consequently, it is possible that dif-
ferent sources (e.g. the statistics of company, the
opinions of key persons) have been used when answer-
ing the questions of the survey. There is also the possi-
bility for over- or underestimation in self-reported
responses [46]. The questionnaires were returned anon-
ymously and thus, the validity and reliability of the
answers could not be investigated. However, some of
our findings are in accordance with other sources,
which support the validity of the responses. In addition,
the background characteristics of the original product
and generic product companies that responded in the
2004 and 2008 surveys were very similar. Besides, the
responses especially in the original product companies
were similar in both surveys. On the other hand, there
were also variations in the trend of answers especially in
the generic product companies between surveys. This
could result from the fact that different companies
responded in 2004 and 2008. Another possible reason is
that impact of GS changed during the four years
between the surveys. However, tracing the impact of GS
Table 7 Impact of generic substitution on the storage of pharmaceutical products by the pharmaceutical companies
Survey 2004 Survey 2008
Original
product
companies
(n = 16)
n (%)
a
Generic
product
companies
(n = 7)
n (%)
a
Total
(n = 23)
n (%)
a
P-
value
Original
product
companies
(n = 15)
n (%)
a
Generic
product
companies
(n = 6)
n (%)
a
Total
(n = 21)
n (%)
a
P-
value
Has generic substitution influenced the storage of
pharmaceutical products by your company?
No* 4 (25) 3 (43) 7 (30) 0.626 10 (67) 3 (50) 13 (62) 0.631
It has caused over-stocking** 9 (56) 2 (29) 11 (48) 0.371 4 (27) 1 (17) 5 (24) 1.000
It has caused problems with the expiry date of
pharmaceutical products***
7 (44) 4 (57) 11 (48) 0.667 3 (20) 3 (50) 6 (29) 0.291
It has caused over-stocking of obligatory
stocks
b ****
4 (25) 1 (14) 5 (22) 1.000 3 (20) - 3 (14) 0.526
It has caused problems with the availability of
pharmaceutical products*****
4 (25) 1 (14) 5 (22) 1.000 2 (13) 3 (50) 5 (24) 0.115
It has complicated the execution of obligatory
storage
b ******
2 (12) 1 (14) 3 (13) 0.684 2 (13) 1 (17) 3 (14) 1.000
It has increased returns of pharmaceutical
products from pharmacies after the new price
corridor is determined
c
- - - - 2 (13) 1 (17) 3 (14) 1.000
* P-value between the 2004 and 2008 surveys in the original product companies (p = 0.032) and in the generic product companies (p = 1.000).
** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.149) and in the generic product companies (p = 1.000).
*** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.252) and in the generic product companies (p = 1.000).
**** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 1.000).
***** P-value between the 2004 and 2008 surveys in the original product companies (p = 0.654) and in the generic product companies (p = 0.266).
****** P-value between the 2004 and 2008 surveys in the original product companies (p = 1.000) and in the generic product companies (p = 1.000).
aThe companies could chose several impacts.
bIn Finland, pharmaceutical companies were obligated to store enough pharmaceutical products in certain medicine groups (e.g. antibiotics, cardiovascular
medicines, analgesics) to cover ten or five months of consumption of that product until the end of the year 2008. The obligatory stock of pharmaceutical
products was based on the average sales of the product during the period from January to September of the previous year. The obligatory storage Act was
amended in 2009.
cThe question did not include this alternative in the 2004 survey.
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Changes in the reported impact of GS on activities of
companies between years 2004 and 2008 should be
interpreted with caution.
This study was limited to the experiences of pharma-
ceutical companies in Finland. The operating environ-
ment of pharmaceutical companies and the practices of
GS vary between countries. This means caution is
needed when comparing the results from other coun-
tries. For instance, there is much variation in the size
and structure of the pharmaceutical markets and the
number of pharmaceutical companies that operate in
the market between countries [1,34,36]. GS by pharma-
cists is mandatory in Finland and in some other coun-
tries (e.g. Sweden, Germany, Denmark) as well as in
some of the states in United States [1,47]. However, in
other countries (e.g. France, Italy, Netherlands, Norway,
Portugal, Australia, Japan) as well as in most of the
states in United States GS is allowed, but is not obli-
gated [1,47-49]. Besides, GS has significantly promoted
competition between pharmaceutical products [11,50]
and influenced the sales and gross margins of companies
in Finland [7] like in some other countries (e.g. United
States, Netherlands, Sweden, Denmark, Germany)
[4-6,8,10]. However, in some countries (e.g. Italy, Spain)
the impact of GS on the sales of products and competi-
tion has been smaller [5,51]. Accordingly, the impacts of
GS on activities other than competition in the compa-
nies may also vary between these countries.
Conclusions
The study suggests that GS impacted the activities of
pharmaceutical companies that represent mainly original
or generic pharmaceutical products in Finland. In addi-
tion, there were some differences, although not statisti-
cally significant, between the surveyed original and
generic product companies regarding the self-reported
impacts of GS. The number of employees and amount
of prescription medicine marketing decreased in many
of the original product companies after the introduction
of GS. In addition, the original product companies
reported problems related to the storage of pharmaceu-
tical products shortly after the reform. In the generic
product companies, the prescription representatives’ vis-
its to pharmacies increased at the beginning of GS.
Furthermore, GS caused problems with the storage of
pharmaceuticals one year and five years after the intro-
duction. This study was based a small group of surveyed
companies and had some limitations. Further investiga-
tions are needed in this field.
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